Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center Mortality goes up in tandem with admission natriuretic peptide levels in patients with severe ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

Patients with heart failure (HF) with preserved ejection fraction (HFpEF) who presented for this study analysis with normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) and ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The same ...

Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a key biomarker for diagnosing heart failure, show a nearly fourfold increased risk for atrial fibrillation (AF) in at-risk ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis, experts suggest.

Please provide your email address to receive an email when new articles are posted on . Baseline N-terminal pro-B natriuretic peptide in patients with HF with preserved ejection fraction accurately ...